Mensah GA, Fuster V, Murray CJL, Roth GA. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82:2350–473. https://doi.org/10.1016/j.jacc.2023.11.007

Article  PubMed  PubMed Central  Google Scholar 

Timmis A, Aboyans V, Vardas P, et al. European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics. Eur Heart J. 2024;ehae466. https://doi.org/10.1093/eurheartj/ehae466

Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–3826. https://doi.org/10.1093/eurheartj/ehad191

Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;130:2354–94. https://doi.org/10.1161/CIR.0000000000000133

Article  PubMed  Google Scholar 

Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670–1676. https://doi.org/10.1056/NEJM199512213332503

Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–677. https://doi.org/10.1056/NEJM199209033271001

The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828. https://doi.org/10.1016/0140-6736(93)92693-N

Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788. https://doi.org/10.1016/s0140-6736(03)14286-9

Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153. https://doi.org/10.1056/NEJM200001203420301

Prosser HC, Peck KY, Dinh D, et al. Role of renin-angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction. Clin Res Cardiol. 2022;111:776–86. https://doi.org/10.1007/s00392-021-01985-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raposeiras-Roubín S, Abu-Assi E, Cespón-Fernández M, et al. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction. Rev Esp Cardiol (Engl Ed). 2020;73:114–22. https://doi.org/10.1016/j.rec.2019.02.012

Article  PubMed  Google Scholar 

Bello AK, Levin A, Tonelli M, et al. Assessment of global kidney health care status. JAMA. 2017;317:1864–81. https://doi.org/10.1001/jama.2017.4046

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhao M-H, Zuo L, et al. China Kidney Disease Network (CK-NET) 2015 annual data report. Kidney Int Suppl. 2011;2019(9):e1–81. https://doi.org/10.1016/j.kisu.2018.11.001

Article  Google Scholar 

Szummer K, Lindhagen L, Evans M, et al. Treatments and mortality trends in cases with and without dialysis Who have an acute myocardial infarction: an 18-year nationwide experience. Circ Cardiovasc Qual Outcomes. 2019;12:e005879. https://doi.org/10.1161/CIRCOUTCOMES.119.005879

Article  PubMed  Google Scholar 

Chen R, Liu C, Zhou P, et al. Prognostic impacts of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute coronary syndrome patients without heart failure. Front Pharmacol. 2022;13:663811. https://doi.org/10.3389/fphar.2022.663811

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorbets E, Labreuche J, Simon T, et al. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. Eur Heart J. 2014;35:1760–8. https://doi.org/10.1093/eurheartj/ehu078

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cespón-Fernández M, Raposeiras-Roubín S, Abu-Assi E, et al. Renin-angiotensin system blockade and risk of heart failure after myocardial infarction based on left ventricular ejection fraction: a retrospective cohort study. Am J Cardiovasc Drugs. 2019;19:487–95. https://doi.org/10.1007/s40256-019-00343-7

Article  CAS  PubMed  Google Scholar 

Evans M, Carrero J-J, Szummer K, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction. J Am Coll Cardiol. 2016;67:1687–97. https://doi.org/10.1016/j.jacc.2016.01.050

Article  CAS  PubMed  Google Scholar 

Li Z, Sun H, Hao Y, et al. Renin-angiotensin system inhibition and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: findings from CCC-ACS project and a nationwide electronic health record-based cohort in China. Eur Heart J Qual Care Clin Outcomes. 2023;9:785–95. https://doi.org/10.1093/ehjqcco/qcad006

Article  PubMed  Google Scholar 

Shen JI, Saxena AB, Montez-Rath ME, et al. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis. Nephrol Dial Transplan. 2017;32:862–9. https://doi.org/10.1093/ndt/gfw053

Article  CAS  Google Scholar 

Lee H-F, See L-C, Chan Y-H, et al. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study. Intern Med J. 2018;48:1123–32. https://doi.org/10.1111/imj.13971

Article  CAS  PubMed  Google Scholar 

Gosmanova EO, Molnar MZ, Naseer A, et al. Longer predialysis ACEi/ARB utilization is associated with reduced postdialysis mortality. Am J Med. 2020;133:1065-1073.e3. https://doi.org/10.1016/j.amjmed.2020.03.037

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farkas JD, Long B, Koyfman A, Menson K. BRASH syndrome: bradycardia, renal failure, AV blockade, shock, and hyperkalemia. J Emerg Med. 2020;59:216–23. https://doi.org/10.1016/j.jemermed.2020.05.001

Article  PubMed  Google Scholar 

Movilli E, Camerini C, Gaggia P, et al. Use of renin-angiotensin system blockers increases serum potassium in anuric hemodialysis patients. Am J Nephrol. 2018;48:79–86. https://doi.org/10.1159/000491552

Article  CAS  PubMed  Google Scholar 

Kido R, Akizawa T, Fukagawa M, et al. Interactive effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers or their combination on survival of hemodialysis patients. Am J Nephrol. 2017;46:439–47. https://doi.org/10.1159/000482013

Article  CAS  PubMed  Google Scholar 

Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int. 2011;80:978–85. https://doi.org/10.1038/ki.2011.228

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838–54. https://doi.org/10.1161/CIRCULATIONAHA.105.594986

Article  PubMed  Google Scholar 

Kiss Z, Ambrus C, Kulcsár I, et al. Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis. J Renin Angiotensin Aldosterone Syst. 2015;16:1021–7. https://doi.org/10.1177/1470320314535276

Article  CAS  PubMed  Google Scholar